THERAVET SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.598 EUR | +0.34% |
|
-6.27% | -58.76% |
| 05-21 | TheraVet SA Announces Early Completion of Patient Recruitment of the Visco-VET Clinical Study | CI |
| 05-07 | FOMO is Back |  |
| Sales 2021 | 1.94M 2.11M 2.87M | Sales 2022 | 1.6M 1.74M 2.37M | Capitalization | 8.06M 8.75M 11.91M |
|---|---|---|---|---|---|
| Net income 2021 | -1M -1.09M -1.48M | Net income 2022 | -2M -2.17M -2.95M | EV / Sales 2021 | 7.08 x |
| Net cash position 2021 | 4.63M 5.03M 6.84M | Net cash position 2022 | 2.14M 2.32M 3.16M | EV / Sales 2022 | 3.7 x |
| P/E ratio 2021 * |
-
| P/E ratio 2022 |
-3.48
x | Employees | 8 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +0.34% | ||
| 1 week | -6.27% | ||
| 1 month | -14.08% | ||
| 3 months | -40.20% | ||
| 6 months | -61.42% | ||
| Current year | -58.76% |
1 week
0.57
0.63
1 month
0.570.73
Current year
0.571.46
1 year
0.572.40
3 years
0.578.56
5 years
0.578.56
10 years
0.578.56
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | - | 17-11-20 | |
Rodolphe Lebrun
DFI | Director of Finance/CFO | - | 23-10-23 |
Celine Molle
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | - | 17-11-20 | |
Simon Wheeler
CHM | Chairman | - | 21-12-19 |
Nesya Goris
BRD | Director/Board Member | - | 21-12-19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 0.598 | +0.34% | 4,671 |
| 24-05-30 | 0.596 | -0.67% | 495 |
| 24-05-29 | 0.6 | -3.54% | 742 |
| 24-05-28 | 0.622 | -0.32% | 3,486 |
| 24-05-27 | 0.624 | -2.19% | 3,802 |
Real-time Euronext Paris, May 31, 2024 at 11:35 am
More quotes
TheraVet SA is specialized in the development of pharmaceutical products for the treatment of osteoarticular diseases in pets.
At the end of 2023, the company had a portfolio of 2 products in the clinical development phase: Visco-Vet for the treatment of limping associated with osteoarthritis in dogs and Biocera-Vet for osseointegration and bone remodeling.
Calendar
2024-06-06
- Shareholders Meeting
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -58.76% | 2.09M | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B | |
| +77.64% | 8.87B |
- Stock Market
- Equities
- ALVET Stock
